Sol-Gel makes $27M derm drug delivery deal
This article was originally published in Scrip
The private Israeli drug delivery company Sol-Gel Technologies has entered into a second development and licensing agreement with an undisclosed US pharmaceutical company. The deal covers the development and commercialisation of a "major" dermatological drug in the US and Canada, Sol-Gel says.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.